LISA MCCORKELL NAMED TO NATURE’S 10: TEN PEOPLE WHO HELPED SHAPE SCIENCE IN 2022
December 14th, 2022
Media contact: firstname.lastname@example.org
Lisa McCorkell, a co-founder of the Patient-Led Research Collaborative (PLRC), has been named to Nature’s 10 – ten people who helped shape science in 2022. Since April 2020, Lisa has worked tirelessly to advance advocacy and research into Long COVID and other viral-onset conditions like ME/CFS and dysautonomia, as well as reforming the field of patient involvement in research. She has co-authored papers on Long COVID, embedding patients into research, the episodic nature of disability, and clinically supporting Long COVID patients, and is an author of the Long COVID Survival Guide. She co-authored a major report, “Advancing Disability Equity and Access in TANF and SNAP For People with Long COVID,” and has advised the White House, CDC, NIH, and Senators Kaine and Pressley on their Long COVID proposals and plans. Lisa has testified to the United States Congress House Committee on Energy and Commerce on Long COVID, and has been involved in dozens of significant advocacy projects since 2020. Additionally, Lisa co-managed PLRC’s $5 million Patient-Led Research Fund, and in 2022 granted out funding to nine teams to advance multiple forms of research into Long COVID, ME/CFS, and dysautonomia.
The Patient-Led Research Collaborative is thrilled that Lisa’s efforts to advance advocacy and research into Long COVID, ME/CFS, and related illnesses is being recognized, and are proud and honored to have her as a leader.
For questions, please contact email@example.com.
About Patient-Led Research Collaborative: Patient-Led Research Collaborative (PLRC) is a multi-disciplinary group of people with lived experience of Long COVID, formed together in April 2020 through the Body Politic COVID-19 Support Group, and were the first to conduct research on Long COVID. PLRC’s work thus far has resulted in the identification of key symptoms, timeline, comorbidities, and possible treatment options for Long COVID, as well as a $4.8 million fund for biomedical research with awards decided by patients, a publication of patient-generated hypotheses, and research into the impact of reinfections, identifying Long Covid phenotypes, Long Covid impact in LMIC countries, and others. They have presented their work to the World Health Organization, United States House of Representatives, National Institutes of Health, and Centers for Disease Control and Prevention, and have influenced Long COVID clinical guidelines and legislation. For more on PLRC, visit patientledresearch.com.